Oruka Therapeutics Announces $200 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
TD Cowen Starts Oruka Therapeutics (ORKA) at Buy
September 16, 2024 5:31 AM EDTTD Cowen analyst Tyler Van Buren initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating.
The analyst comments "Oruka is backed by sophisticated mAb engineering and both ORKA-001 and ORKA-002 have a high PoS by targeting the same... More
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
September 12, 2024 4:47 PM EDTJefferies analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target of $40.00.
The analyst comments "We initiate ORKA at BUY and see high probability of success for two YTE modified "long-acting" enhanced antibodies for... More
